Intellia Therapeutics, Inc. (NTLA) stock
Close on Nov 11, 2026Market cap $1.60BP/E –Yield –
Intellia Therapeutics, Inc. saw revenue fall 8.1% to $52.89M over the twelve months to Sep 30, 2026. Free cash flow was -$358.08M. At the latest close the market valued the company at $1.60B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.60B
- P/E ratio
- –
- Price to sales
- 30.23
- Price to book
- 2.61
- Dividend yield
- –
- Free cash flow yield
- -22.40%
Fundamentals
- Revenue
- $52.89M
- Net income
- -$426.14M
- EPS, diluted
- -$3.35
- Free cash flow
- -$358.08M
- Book value per share
- $4.37
- Diluted shares
- 140M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $11.17
- Open
- $11.30
- Day's range
- $11.13 – $11.64
- Volume
- 3,035,481
- Average volume (20 days)
- 4,236,351
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 2.11
- 52-week range
- $7.95 – $18.48
- RSI (14 days)
- 46.4
- Volatility (1 year)
- 76.1%
- Relative volume
- 0.70×
- WACC
- 15.0%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NTLA | S&P 500 | Difference | NTLA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.7% | -2.4% | −10.3 pts | ||
| 3 months | -5.1% | -1.2% | −3.9 pts | ||
| Year to date | +26.9% | +12.3% | +14.6 pts | ||
| 1 year | +12.1% | +12.4% | −0.4 pts | ||
| 3 years | -52.7% | +78.8% | −131.5 pts | -22.1% | +21.4% |
| 5 years | -91.3% | +75.2% | −166.4 pts | -38.6% | +11.9% |
| 10 years | -22.9% | +311.1% | −334.0 pts | -2.6% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Intellia Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Intellia Therapeutics
In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics is a biopharmaceutical company that develops treatments utilizing CRISPR gene editing, lipid nanoparticles, and oligonucleotide technologies to address severe genetic diseases. Its lead investigational product candidates are lonvoguran ziclumeran, designed for hereditary angioedema, and nexiguran ziclumeran, developed for transthyretin amyloidosis. Both therapies are designed as one-time intravenous infusions. The company also develops preclinical and clinical-stage programs in cellular therapies, including universal CAR-T cell treatments. Its therapies target individuals diagnosed with rare and life-threatening conditions, while the business works alongside healthcare prescribers, clinical institutions, and pharmaceutical collaboration partners such as Regeneron.
Company profile, executives and historyIntellia Therapeutics stock: common questions
What is Intellia Therapeutics's stock price?
NTLA closed at $11.41 on Nov 11, 2026, up 2.15% on the day. Over the past 52 weeks it traded between $7.95 and $18.48.
What is Intellia Therapeutics's market cap?
Intellia Therapeutics was worth $1.60B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NTLA's P/E ratio?
Intellia Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.35), so it has no meaningful P/E ratio.
How much revenue does Intellia Therapeutics make?
Intellia Therapeutics reported revenue of $52.89M for the twelve months to Sep 30, 2026, down 8.1% from a year earlier.
Does Intellia Therapeutics pay a dividend?
No. Intellia Therapeutics has not paid a cash dividend over the last twelve months.
When does Intellia Therapeutics report earnings next?
Intellia Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NTLA stock performed over the past year?
Including dividends, NTLA returned +12.1% over the past year, against +12.4% for the S&P 500.
How many NTLA shares are sold short?
44M shares were sold short at the latest FINRA report, 32.31% of the float, or 11.1 days of average trading volume.
Who are Intellia Therapeutics's competitors?
Companies most similar to Intellia Therapeutics by business, industry and size include EDIT, DTIL, CRSP, WVE, SGMOQ.
See a number that looks wrong?